Novo Nordisk’s phase 3 STEP Young trial found that weekly semaglutide, combined with lifestyle intervention, substantially lowered body mass index in children ages 6 to under 12 with obesity, potentially supporting applications for treatment at younger ages.
The multinational, double-blind study assigned 167 children to semaglutide or placebo while both groups followed lifestyle measures. After 68 weeks, estimated mean BMI fell 17.4% with semaglutide and rose 2.2% with placebo, a difference of −19.7 percentage points favoring the drug (P<0.001).
Using an analysis based on participants’ assigned treatment regimen, BMI declined 13.5% in the semaglutide group and increased 2.7% with placebo. Novo Nordisk said 83% of treated children improved their BMI category, compared with 23.5% of those receiving placebo. Under the efficacy estimand, 40.4% of children taking semaglutide were below the study’s obesity threshold at week 68, versus none in the placebo group.
Severe obesity was advanced at baseline: more than 85% of participants were in class II or class III. Maximum doses were 1.7 mg or 2.4 mg once weekly, determined by baseline weight.
Participants remained on treatment through week 104 and then entered a seven-week off-drug safety follow-up. At week 104, the treatment-regimen analysis showed BMI down 9.4% with semaglutide and up 8.4% with placebo. Novo said those secondary results were not adjusted for multiple comparisons and should not be considered definitive.
Novo reported a safety profile consistent with earlier semaglutide trials and no identified safety concerns involving growth or puberty. The company listed nausea, diarrhea, vomiting, constipation and abdominal pain among common side effects and repeated Wegovy’s boxed warning on thyroid tumors, including medullary thyroid carcinoma.
Semaglutide is a glucagon-like peptide-1 receptor agonist that mimics a gut hormone involved in appetite and blood-sugar control. Wegovy is approved for weight management, while Ozempic and Rybelsus use the same active ingredient for different indications.
The FDA’s Wegovy label covers adults and children ages 12 and older with obesity; it does not authorize obesity treatment in children under 12. Novo said the STEP Young findings could support applications for expanded approval, but the trial itself does not change the label.
Ania M. Jastreboff, a Yale School of Medicine professor and director of the Yale Obesity Research Center, said in Novo’s announcement that treatment was associated with improvements in several cardiometabolic measures and could alter the course of severe childhood obesity. The National quoted England’s chief medical officer, Chris Whitty, as saying pediatric use was not socially or medically acceptable because the drugs are not benign.
The study included only 167 children with substantial obesity and tested semaglutide alongside lifestyle intervention. Its 104-week treatment period and seven-week follow-up cannot resolve long-term developmental risks or show how weight changes after discontinuation. Novo cited an estimate that 177 million children and adolescents ages 5 to 19 worldwide had obesity in 2025, illustrating the scale of the problem.



